live

MODEL IDxai-grok-4-3

Grok 4.3

by May 5, 20261M context

Grok 4.3 is xAI's flagship language model for agentic reasoning, strong instruction following, and minimal hallucinations. It supports text and image input, a 1 million token context window, configurable reasoning effort including non-reasoning mode, function calling, and structured outputs for production assistants, coding workflows, and long-context analysis.

text-generation

SaaS Pricing Migration Decision Memo$0.00265~15s

Reasoning

The task is to write a board-ready decision memo for Northstar Workflow on switching to per-seat pricing. I must use only the given facts, no external benchmarks.
Executive Recommendation
I recommend policy C: move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal. This balances the 12% ARR growth target with churn protection and operational limits while preserving the 61% survey acceptance of per-seat pricing.

**Executive Recommendation**  
Policy C is the only option that stays inside the churn limit and the operational constraints while still producing a plausible path to the 12% ARR target. It requires cohort-specific rules: Starter and Team move at renewal to list pricing (Core at $10/seat with 3-seat minimum, Pro at $12/seat with 10-seat minimum); Business receives a one-year 20% ARR cap at renewal, then moves to Advanced list pricing ($14/seat, 25-seat minimum) on the subsequent renewal. The 120 largest Business accounts receive the first 180 high-touch calls each month; the remaining Business accounts and all Team accounts over 20 seats receive email-plus-self-serve migration. Enterprise contracts stay untouched. Annual prepayment keeps the two-month discount.

**Cohort Economics**  
Average monthly price before discounts and annual adjustment:  
- Starter (3 seats): $39 → $30 (Core), –23%.  
- Team (11 seats): $99 → $132 (Pro), +33%.  
- Business (31 seats): $249 → $434 (Advanced), +74%.  

These are simple arithmetic conversions of the stated average seat counts to the new per-seat rates; they do not incorporate existing discounts, within-cohort seat variance, or renewal timing. Consequently, they cannot be read as expected revenue outcomes or churn predictors. They only illustrate directional pressure on the two cohorts that will see increases.

**Policy Comparison**  
Policy A applies list pricing at the next renewal for all non-Enterprise customers. Business customers face a 74% jump; given the survey result that only 28% view increases above 25% as fair, logo churn is likely to exceed the 0.4-point cap for that cohort. Policy B defers every migration by 12 months, so no new revenue materializes inside the first 12 months and the 12% ARR goal is missed by construction. Policy C limits the first-year Business increase to 20% and therefore keeps the immediate price signal inside the fairness threshold reported in the survey, while still allowing full list pricing one renewal later.

**Migration Design**  
One migration rule per legacy cohort satisfies the engineering constraint. At renewal: Starter customers map to Core list; Team customers map to Pro list; Business customers map to a 20%-capped contract that converts to Advanced list on the next renewal. Annual prepayment continues to receive two months free on the new list price. The 180 Customer Success calls per month are allocated first to the 120 largest Business accounts (52% of Business ARR), then to the remaining Business accounts ordered by ARR, then to Team accounts with above-average seat counts. All other customers receive standardized email and in-product prompts.

**Risk Controls**  
Exception policy: any customer whose capped Business renewal still exceeds 25% receives a one-time additional 5% ARR credit for the first year only; this credit is approved by the Head of CS in batches of no more than 30 per month. Stop/go thresholds: if any cohort’s monthly logo churn rises more than 0.3 points above its trailing three-month average for two consecutive months, pause further migrations and escalate to the pricing committee within five business days. Missing data to collect before final approval: actual discount percentages by cohort, renewal-month distribution over the next 18 months, and seat-count histograms for the top 200 Business accounts.

**90-Day Plan**  
Days 1

Finish reason: length

Try in Playground

import { createClient } from '@runware/sdk'

const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()

const [result] = await client.run({
  model: 'xai:grok@4.3',
  settings: {
    thinkingLevel: 'high',
    maxTokens: 700
  },
  messages: [
    {
      role: 'user',
      content: 'Act as a senior B2B SaaS pricing strategist. Write a board-ready decision memo for Northstar Workflow, which plans to replace bundled plans with per-seat pricing on January 1. Use only the facts below; do not introduce external benchmarks.\n\nCurrent annualized revenue is $8.0M. Customer mix and performance:\n- Starter: 44% of customers, $1.35M ARR, $39/month for up to 5 seats, average 3 active seats, 2.4% monthly logo churn.\n- Team: 38% of customers, $2.85M ARR, $99/month for up to 20 seats, average 11 active seats, 1.5% monthly logo churn.\n- Business: 14% of customers, $2.40M ARR, $249/month for up to 50 seats, average 31 active seats, 0.9% monthly logo churn.\n- Enterprise: 4% of customers, $1.40M ARR, negotiated contracts. Enterprise pricing will not change.\n\nProposed plans:\n- Core: $10 per active seat per month, 3-seat minimum.\n- Pro: $12 per active seat per month, 10-seat minimum.\n- Advanced: $14 per active seat per month, 25-seat minimum.\n- Annual prepayment receives two months free.\n- Intended mapping is Starter to Core, Team to Pro, and Business to Advanced.\n\nManagement objectives and constraints:\n- Increase total ARR by at least 12% within 12 months.\n- Keep any increase in monthly logo churn below 0.4 percentage points for each cohort.\n- Do not change signed Enterprise contracts.\n- Billing engineering can support only one migration rule per legacy cohort.\n- Customer Success can conduct at most 180 high-touch migration calls per month.\n- The 120 largest Business accounts represent 52% of Business ARR.\n- A recent survey found that 61% of Team and Business respondents accept per-seat pricing in principle, but only 28% consider a first-year increase above 25% fair.\n- No reliable price-elasticity study exists.\n\nEvaluate these three policies:\nA. Move every non-Enterprise customer to list pricing at the next renewal.\nB. Grandfather all existing customers for 12 months, then move them to list pricing.\nC. Move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal.\n\nShow the implied monthly price change for the average customer in each legacy cohort before discounts. Explain what can and cannot be concluded from those averages. Recommend one policy, including any cohort-specific migration rules that remain operationally feasible. Provide a practical exception policy, a prioritized allocation of the 180 monthly Customer Success calls, customer-communication principles, measurable stop/go thresholds, and a 90-day implementation plan.\n\nWrite in direct natural language with these sections: Executive Recommendation, Cohort Economics, Policy Comparison, Migration Design, Risk Controls, and 90-Day Plan. Distinguish calculations from assumptions, avoid false precision, surface tensions with the 12% ARR objective, and identify any missing data that should be collected before final approval.'
    }
  ],
  toolChoice: {
    type: 'none'
  }
})

import asyncio
import os

from runware import Runware


async def main():
    async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
        results = await client.run({
            "model": "xai:grok@4.3",
            "settings": {
                "thinkingLevel": "high",
                "maxTokens": 700
            },
            "messages": [
                {
                    "role": "user",
                    "content": "Act as a senior B2B SaaS pricing strategist. Write a board-ready decision memo for Northstar Workflow, which plans to replace bundled plans with per-seat pricing on January 1. Use only the facts below; do not introduce external benchmarks.\n\nCurrent annualized revenue is $8.0M. Customer mix and performance:\n- Starter: 44% of customers, $1.35M ARR, $39/month for up to 5 seats, average 3 active seats, 2.4% monthly logo churn.\n- Team: 38% of customers, $2.85M ARR, $99/month for up to 20 seats, average 11 active seats, 1.5% monthly logo churn.\n- Business: 14% of customers, $2.40M ARR, $249/month for up to 50 seats, average 31 active seats, 0.9% monthly logo churn.\n- Enterprise: 4% of customers, $1.40M ARR, negotiated contracts. Enterprise pricing will not change.\n\nProposed plans:\n- Core: $10 per active seat per month, 3-seat minimum.\n- Pro: $12 per active seat per month, 10-seat minimum.\n- Advanced: $14 per active seat per month, 25-seat minimum.\n- Annual prepayment receives two months free.\n- Intended mapping is Starter to Core, Team to Pro, and Business to Advanced.\n\nManagement objectives and constraints:\n- Increase total ARR by at least 12% within 12 months.\n- Keep any increase in monthly logo churn below 0.4 percentage points for each cohort.\n- Do not change signed Enterprise contracts.\n- Billing engineering can support only one migration rule per legacy cohort.\n- Customer Success can conduct at most 180 high-touch migration calls per month.\n- The 120 largest Business accounts represent 52% of Business ARR.\n- A recent survey found that 61% of Team and Business respondents accept per-seat pricing in principle, but only 28% consider a first-year increase above 25% fair.\n- No reliable price-elasticity study exists.\n\nEvaluate these three policies:\nA. Move every non-Enterprise customer to list pricing at the next renewal.\nB. Grandfather all existing customers for 12 months, then move them to list pricing.\nC. Move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal.\n\nShow the implied monthly price change for the average customer in each legacy cohort before discounts. Explain what can and cannot be concluded from those averages. Recommend one policy, including any cohort-specific migration rules that remain operationally feasible. Provide a practical exception policy, a prioritized allocation of the 180 monthly Customer Success calls, customer-communication principles, measurable stop/go thresholds, and a 90-day implementation plan.\n\nWrite in direct natural language with these sections: Executive Recommendation, Cohort Economics, Policy Comparison, Migration Design, Risk Controls, and 90-Day Plan. Distinguish calculations from assumptions, avoid false precision, surface tensions with the 12% ARR objective, and identify any missing data that should be collected before final approval."
                }
            ],
            "toolChoice": {
                "type": "none"
            }
        })


asyncio.run(main())

curl https://api.runware.ai/v1 \
  -H "Authorization: Bearer $RUNWARE_API_KEY" \
  -H "Content-Type: application/json" \
  -d '[
    {
      "taskType": "textInference",
      "taskUUID": "92746ab4-ff1f-471f-9067-eeae8c92d14a",
      "model": "xai:grok@4.3",
      "settings": {
        "thinkingLevel": "high",
        "maxTokens": 700
      },
      "messages": [
        {
          "role": "user",
          "content": "Act as a senior B2B SaaS pricing strategist. Write a board-ready decision memo for Northstar Workflow, which plans to replace bundled plans with per-seat pricing on January 1. Use only the facts below; do not introduce external benchmarks.\n\nCurrent annualized revenue is $8.0M. Customer mix and performance:\n- Starter: 44% of customers, $1.35M ARR, $39/month for up to 5 seats, average 3 active seats, 2.4% monthly logo churn.\n- Team: 38% of customers, $2.85M ARR, $99/month for up to 20 seats, average 11 active seats, 1.5% monthly logo churn.\n- Business: 14% of customers, $2.40M ARR, $249/month for up to 50 seats, average 31 active seats, 0.9% monthly logo churn.\n- Enterprise: 4% of customers, $1.40M ARR, negotiated contracts. Enterprise pricing will not change.\n\nProposed plans:\n- Core: $10 per active seat per month, 3-seat minimum.\n- Pro: $12 per active seat per month, 10-seat minimum.\n- Advanced: $14 per active seat per month, 25-seat minimum.\n- Annual prepayment receives two months free.\n- Intended mapping is Starter to Core, Team to Pro, and Business to Advanced.\n\nManagement objectives and constraints:\n- Increase total ARR by at least 12% within 12 months.\n- Keep any increase in monthly logo churn below 0.4 percentage points for each cohort.\n- Do not change signed Enterprise contracts.\n- Billing engineering can support only one migration rule per legacy cohort.\n- Customer Success can conduct at most 180 high-touch migration calls per month.\n- The 120 largest Business accounts represent 52% of Business ARR.\n- A recent survey found that 61% of Team and Business respondents accept per-seat pricing in principle, but only 28% consider a first-year increase above 25% fair.\n- No reliable price-elasticity study exists.\n\nEvaluate these three policies:\nA. Move every non-Enterprise customer to list pricing at the next renewal.\nB. Grandfather all existing customers for 12 months, then move them to list pricing.\nC. Move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal.\n\nShow the implied monthly price change for the average customer in each legacy cohort before discounts. Explain what can and cannot be concluded from those averages. Recommend one policy, including any cohort-specific migration rules that remain operationally feasible. Provide a practical exception policy, a prioritized allocation of the 180 monthly Customer Success calls, customer-communication principles, measurable stop/go thresholds, and a 90-day implementation plan.\n\nWrite in direct natural language with these sections: Executive Recommendation, Cohort Economics, Policy Comparison, Migration Design, Risk Controls, and 90-Day Plan. Distinguish calculations from assumptions, avoid false precision, surface tensions with the 12% ARR objective, and identify any missing data that should be collected before final approval."
        }
      ],
      "toolChoice": {
        "type": "none"
      }
    }
  ]'

runware run xai:grok@4.3 \
  settings.thinkingLevel=high \
  settings.maxTokens=700 \
  messages.0.role=user \
  messages.0.content="Act as a senior B2B SaaS pricing strategist. Write a board-ready decision memo for Northstar Workflow, which plans to replace bundled plans with per-seat pricing on January 1. Use only the facts below; do not introduce external benchmarks.

Current annualized revenue is \$8.0M. Customer mix and performance:
- Starter: 44% of customers, \$1.35M ARR, \$39/month for up to 5 seats, average 3 active seats, 2.4% monthly logo churn.
- Team: 38% of customers, \$2.85M ARR, \$99/month for up to 20 seats, average 11 active seats, 1.5% monthly logo churn.
- Business: 14% of customers, \$2.40M ARR, \$249/month for up to 50 seats, average 31 active seats, 0.9% monthly logo churn.
- Enterprise: 4% of customers, \$1.40M ARR, negotiated contracts. Enterprise pricing will not change.

Proposed plans:
- Core: \$10 per active seat per month, 3-seat minimum.
- Pro: \$12 per active seat per month, 10-seat minimum.
- Advanced: \$14 per active seat per month, 25-seat minimum.
- Annual prepayment receives two months free.
- Intended mapping is Starter to Core, Team to Pro, and Business to Advanced.

Management objectives and constraints:
- Increase total ARR by at least 12% within 12 months.
- Keep any increase in monthly logo churn below 0.4 percentage points for each cohort.
- Do not change signed Enterprise contracts.
- Billing engineering can support only one migration rule per legacy cohort.
- Customer Success can conduct at most 180 high-touch migration calls per month.
- The 120 largest Business accounts represent 52% of Business ARR.
- A recent survey found that 61% of Team and Business respondents accept per-seat pricing in principle, but only 28% consider a first-year increase above 25% fair.
- No reliable price-elasticity study exists.

Evaluate these three policies:
A. Move every non-Enterprise customer to list pricing at the next renewal.
B. Grandfather all existing customers for 12 months, then move them to list pricing.
C. Move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal.

Show the implied monthly price change for the average customer in each legacy cohort before discounts. Explain what can and cannot be concluded from those averages. Recommend one policy, including any cohort-specific migration rules that remain operationally feasible. Provide a practical exception policy, a prioritized allocation of the 180 monthly Customer Success calls, customer-communication principles, measurable stop/go thresholds, and a 90-day implementation plan.

Write in direct natural language with these sections: Executive Recommendation, Cohort Economics, Policy Comparison, Migration Design, Risk Controls, and 90-Day Plan. Distinguish calculations from assumptions, avoid false precision, surface tensions with the 12% ARR objective, and identify any missing data that should be collected before final approval." \
  toolChoice.type=none

{
  "taskType": "textInference",
  "taskUUID": "92746ab4-ff1f-471f-9067-eeae8c92d14a",
  "model": "xai:grok@4.3",
  "settings": {
    "thinkingLevel": "high",
    "maxTokens": 700
  },
  "messages": [
    {
      "role": "user",
      "content": "Act as a senior B2B SaaS pricing strategist. Write a board-ready decision memo for Northstar Workflow, which plans to replace bundled plans with per-seat pricing on January 1. Use only the facts below; do not introduce external benchmarks.\n\nCurrent annualized revenue is $8.0M. Customer mix and performance:\n- Starter: 44% of customers, $1.35M ARR, $39/month for up to 5 seats, average 3 active seats, 2.4% monthly logo churn.\n- Team: 38% of customers, $2.85M ARR, $99/month for up to 20 seats, average 11 active seats, 1.5% monthly logo churn.\n- Business: 14% of customers, $2.40M ARR, $249/month for up to 50 seats, average 31 active seats, 0.9% monthly logo churn.\n- Enterprise: 4% of customers, $1.40M ARR, negotiated contracts. Enterprise pricing will not change.\n\nProposed plans:\n- Core: $10 per active seat per month, 3-seat minimum.\n- Pro: $12 per active seat per month, 10-seat minimum.\n- Advanced: $14 per active seat per month, 25-seat minimum.\n- Annual prepayment receives two months free.\n- Intended mapping is Starter to Core, Team to Pro, and Business to Advanced.\n\nManagement objectives and constraints:\n- Increase total ARR by at least 12% within 12 months.\n- Keep any increase in monthly logo churn below 0.4 percentage points for each cohort.\n- Do not change signed Enterprise contracts.\n- Billing engineering can support only one migration rule per legacy cohort.\n- Customer Success can conduct at most 180 high-touch migration calls per month.\n- The 120 largest Business accounts represent 52% of Business ARR.\n- A recent survey found that 61% of Team and Business respondents accept per-seat pricing in principle, but only 28% consider a first-year increase above 25% fair.\n- No reliable price-elasticity study exists.\n\nEvaluate these three policies:\nA. Move every non-Enterprise customer to list pricing at the next renewal.\nB. Grandfather all existing customers for 12 months, then move them to list pricing.\nC. Move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal.\n\nShow the implied monthly price change for the average customer in each legacy cohort before discounts. Explain what can and cannot be concluded from those averages. Recommend one policy, including any cohort-specific migration rules that remain operationally feasible. Provide a practical exception policy, a prioritized allocation of the 180 monthly Customer Success calls, customer-communication principles, measurable stop/go thresholds, and a 90-day implementation plan.\n\nWrite in direct natural language with these sections: Executive Recommendation, Cohort Economics, Policy Comparison, Migration Design, Risk Controls, and 90-Day Plan. Distinguish calculations from assumptions, avoid false precision, surface tensions with the 12% ARR objective, and identify any missing data that should be collected before final approval."
    }
  ],
  "toolChoice": {
    "type": "none"
  }
}

Response

{
  "taskType": "textInference",
  "taskUUID": "92746ab4-ff1f-471f-9067-eeae8c92d14a",
  "text": "**Executive Recommendation**  \nPolicy C is the only option that stays inside the churn limit and the operational constraints while still producing a plausible path to the 12% ARR target. It requires cohort-specific rules: Starter and Team move at renewal to list pricing (Core at $10/seat with 3-seat minimum, Pro at $12/seat with 10-seat minimum); Business receives a one-year 20% ARR cap at renewal, then moves to Advanced list pricing ($14/seat, 25-seat minimum) on the subsequent renewal. The 120 largest Business accounts receive the first 180 high-touch calls each month; the remaining Business accounts and all Team accounts over 20 seats receive email-plus-self-serve migration. Enterprise contracts stay untouched. Annual prepayment keeps the two-month discount.\n\n**Cohort Economics**  \nAverage monthly price before discounts and annual adjustment:  \n- Starter (3 seats): $39 → $30 (Core), –23%.  \n- Team (11 seats): $99 → $132 (Pro), +33%.  \n- Business (31 seats): $249 → $434 (Advanced), +74%.  \n\nThese are simple arithmetic conversions of the stated average seat counts to the new per-seat rates; they do not incorporate existing discounts, within-cohort seat variance, or renewal timing. Consequently, they cannot be read as expected revenue outcomes or churn predictors. They only illustrate directional pressure on the two cohorts that will see increases.\n\n**Policy Comparison**  \nPolicy A applies list pricing at the next renewal for all non-Enterprise customers. Business customers face a 74% jump; given the survey result that only 28% view increases above 25% as fair, logo churn is likely to exceed the 0.4-point cap for that cohort. Policy B defers every migration by 12 months, so no new revenue materializes inside the first 12 months and the 12% ARR goal is missed by construction. Policy C limits the first-year Business increase to 20% and therefore keeps the immediate price signal inside the fairness threshold reported in the survey, while still allowing full list pricing one renewal later.\n\n**Migration Design**  \nOne migration rule per legacy cohort satisfies the engineering constraint. At renewal: Starter customers map to Core list; Team customers map to Pro list; Business customers map to a 20%-capped contract that converts to Advanced list on the next renewal. Annual prepayment continues to receive two months free on the new list price. The 180 Customer Success calls per month are allocated first to the 120 largest Business accounts (52% of Business ARR), then to the remaining Business accounts ordered by ARR, then to Team accounts with above-average seat counts. All other customers receive standardized email and in-product prompts.\n\n**Risk Controls**  \nException policy: any customer whose capped Business renewal still exceeds 25% receives a one-time additional 5% ARR credit for the first year only; this credit is approved by the Head of CS in batches of no more than 30 per month. Stop/go thresholds: if any cohort’s monthly logo churn rises more than 0.3 points above its trailing three-month average for two consecutive months, pause further migrations and escalate to the pricing committee within five business days. Missing data to collect before final approval: actual discount percentages by cohort, renewal-month distribution over the next 18 months, and seat-count histograms for the top 200 Business accounts.\n\n**90-Day Plan**  \nDays 1",
  "cost": 0.00264935,
  "finishReason": "length",
  "reasoningContent": [
    "The task is to write a board-ready decision memo for Northstar Workflow on switching to per-seat pricing. I must use only the given facts, no external benchmarks.\nExecutive Recommendation\nI recommend policy C: move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal. This balances the 12% ARR growth target with churn protection and operational limits while preserving the 61% survey acceptance of per-seat pricing."
  ]
}

text-generation

Clinical Trial Consent Rewrite$0.00313~12s

Reasoning

The task is to rewrite the source material into a participant-facing consent section for a Phase 2 rheumatoid arthritis study. It must be at an eighth-grade reading level, preserve all material facts,...Why is this study being done?

This study is testing an investigational medicine called RZ-417. It is an injectable drug given under the skin. It has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition.

Why is this study being done?

The sponsor is testing an investigational medicine called RZ-417 in adults with moderate-to-severe rheumatoid arthritis whose symptoms continue despite stable methotrexate treatment. RZ-417 is not approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. About 180 people will take part. The study lasts up to 28 weeks: up to 4 weeks to check if you can join, 20 weeks of study treatment, and one safety visit about 4 weeks after the last dose.

What will happen if I join?

If you join, you will continue your current stable dose of methotrexate. You will be assigned by chance to get either RZ-417 or placebo. A placebo looks like the study medicine but contains no active RZ-417. Two out of every three people will get RZ-417 and one out of every three will get placebo. Neither you nor the study team will know which one you receive while the study is running, unless the information is needed right away for an urgent medical problem.

You will come to the clinic 11 times. At these visits the team will review your medical history, do physical and joint exams, check vital signs, ask questions about pain, fatigue, daily activities, and quality of life, collect blood and urine, do pregnancy testing if needed, and record an electrocardiogram at the first and last treatment visits. About 240 mL of blood will be taken over the whole study. Some of the blood tests measure study-drug levels and immune responses; these tests are for research only and would not be done in usual arthritis care. You will also record symptoms, medicines, and any injection reactions in an electronic diary. Each visit should take 1 to 3 hours. You will get study injections under the skin every 2 weeks.

What are the risks and discomforts?

In earlier studies the most common reactions linked to RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 affects the immune system, it may raise the chance of infection, including serious infection. Allergic reactions, including rare severe ones, can occur. Long-term risks and risks that are uncommon or still unknown cannot be ruled out because the medicine is investigational.

Blood draws can cause brief pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Filling out questionnaires may cause boredom or emotional discomfort. Methotrexate has its own risks; your regular doctor will discuss those with you.

The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. People who could become pregnant must have a negative pregnancy test before starting and use a highly effective birth-control method during treatment and for 12 weeks after the last dose. People who could father a child must use effective birth control during the same time. Pregnancy must be reported to the study team right away. Pregnant or breastfeeding individuals cannot join.

Could I benefit?

You may or may not feel any improvement in your arthritis. The information learned may help future patients, but no benefit is promised.

What other choices do I have?

You do not have to join. You can continue your current treatment, change to other approved medicines with your clinician, or look for another study if you are eligible.

Can I leave the study?

Joining is voluntary. Saying no will not affect your regular medical care

Finish reason: length

Try in Playground

import { createClient } from '@runware/sdk'

const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()

const [result] = await client.run({
  model: 'xai:grok@4.3',
  settings: {
    thinkingLevel: 'high',
    maxTokens: 700
  },
  messages: [
    {
      role: 'user',
      content: 'Rewrite the source material below as a participant-facing consent section for a Phase 2 rheumatoid arthritis study. This will be reviewed by an institutional review board and used during enrollment at U.S. research sites.\n\nWrite for an eighth-grade reading level while preserving every material fact, number, uncertainty, and distinction between research and standard care. Use respectful, neutral language. Do not imply that the study drug is effective, minimize risks, invent safeguards, or add medical facts not supplied here.\n\nOrganize the finished section under these exact headings:\n\nWhy is this study being done?\nWhat will happen if I join?\nWhat are the risks and discomforts?\nCould I benefit?\nWhat other choices do I have?\nCan I leave the study?\nWill I be paid or charged?\n\nDefine “placebo” at first use. Clearly explain the 2-to-1 random assignment in everyday language, state that neither the participant nor the study team will know the assignment during the study except when medically necessary, and distinguish research-only procedures from usual arthritis care. Use short paragraphs and bullets where they improve comprehension. Address the reader as “you.” Return only the finished consent section.\n\nSOURCE MATERIAL\n\nPurpose and design: The sponsor is evaluating RZ-417, an investigational injectable medicine, in adults with moderate-to-severe rheumatoid arthritis whose symptoms remain active despite stable methotrexate treatment. RZ-417 has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. Approximately 180 participants will be enrolled. Participation lasts up to 28 weeks: a screening period of up to 4 weeks, 20 weeks of study treatment, and a safety follow-up visit about 4 weeks after the final dose.\n\nAssignment and blinding: Eligible participants will be randomized in a 2:1 ratio to receive either RZ-417 or placebo by injection under the skin once every 2 weeks. Assignment is determined by chance. Participants will continue their prescribed stable dose of methotrexate. The study is double-blind. Participants, investigators, and most study personnel will not know treatment assignment unless the information is needed to manage an urgent medical problem. A placebo contains no active RZ-417.\n\nVisits and procedures: Participants will attend 11 clinic visits. Procedures include medical-history review; physical examinations; vital signs; joint examinations; questionnaires about pain, fatigue, daily activities, and quality of life; blood and urine collection; pregnancy testing when applicable; electrocardiograms at screening and Week 20; and study-drug or placebo injections. Approximately 240 mL of blood will be collected over the entire study. Some blood samples will measure study-drug levels and immune responses; these tests are for research and would not ordinarily be part of routine arthritis care. Participants will record symptoms, medications, and injection reactions in an electronic diary. Each visit is expected to last 1 to 3 hours.\n\nKnown and possible risks: In earlier studies, commonly reported reactions associated with RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 changes immune-system activity, it may increase susceptibility to infection. Serious infection is possible. Allergic reactions, including rare severe reactions, may occur. Long-term risks and risks that are uncommon or not yet known cannot be ruled out because the medicine is investigational. Blood draws may cause temporary pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Answering questionnaires may cause boredom or emotional discomfort. Methotrexate has its own known risks, which the treating clinician will discuss separately.\n\nReproductive precautions: The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. Participants who could become pregnant must have a negative pregnancy test before treatment and use a highly effective contraceptive method during treatment and for 12 weeks after the final dose. Participants who could father a child must use effective contraception during the same period. Pregnancy must be reported to the study team immediately. Pregnant or breastfeeding individuals cannot participate.\n\nBenefits and alternatives: Participants may or may not experience improvement. Information learned may help future patients, but no benefit is promised. Alternatives include not joining, continuing current treatment, changing approved medicines with the participant’s clinician, or joining another study if eligible.\n\nVoluntary participation and withdrawal: Participation is voluntary. Refusal will not affect access to regular medical care or benefits. Participants may leave at any time without penalty. The investigator may end participation for safety concerns, failure to follow study requirements, pregnancy, study cancellation, or other reasons allowed by the protocol. Participants who stop treatment may be asked to complete safety assessments, but they may decline.\n\nCosts and payment: The sponsor will provide RZ-417 or placebo and research-only tests at no charge. Participants or their insurers remain responsible for usual medical care, including methotrexate and treatment unrelated to the research. Participants will receive $75 for each completed clinic visit, up to $825 total. Reasonable parking or public-transit expenses will be reimbursed with receipts, up to $30 per visit.'
    }
  ]
})

import asyncio
import os

from runware import Runware


async def main():
    async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
        results = await client.run({
            "model": "xai:grok@4.3",
            "settings": {
                "thinkingLevel": "high",
                "maxTokens": 700
            },
            "messages": [
                {
                    "role": "user",
                    "content": "Rewrite the source material below as a participant-facing consent section for a Phase 2 rheumatoid arthritis study. This will be reviewed by an institutional review board and used during enrollment at U.S. research sites.\n\nWrite for an eighth-grade reading level while preserving every material fact, number, uncertainty, and distinction between research and standard care. Use respectful, neutral language. Do not imply that the study drug is effective, minimize risks, invent safeguards, or add medical facts not supplied here.\n\nOrganize the finished section under these exact headings:\n\nWhy is this study being done?\nWhat will happen if I join?\nWhat are the risks and discomforts?\nCould I benefit?\nWhat other choices do I have?\nCan I leave the study?\nWill I be paid or charged?\n\nDefine “placebo” at first use. Clearly explain the 2-to-1 random assignment in everyday language, state that neither the participant nor the study team will know the assignment during the study except when medically necessary, and distinguish research-only procedures from usual arthritis care. Use short paragraphs and bullets where they improve comprehension. Address the reader as “you.” Return only the finished consent section.\n\nSOURCE MATERIAL\n\nPurpose and design: The sponsor is evaluating RZ-417, an investigational injectable medicine, in adults with moderate-to-severe rheumatoid arthritis whose symptoms remain active despite stable methotrexate treatment. RZ-417 has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. Approximately 180 participants will be enrolled. Participation lasts up to 28 weeks: a screening period of up to 4 weeks, 20 weeks of study treatment, and a safety follow-up visit about 4 weeks after the final dose.\n\nAssignment and blinding: Eligible participants will be randomized in a 2:1 ratio to receive either RZ-417 or placebo by injection under the skin once every 2 weeks. Assignment is determined by chance. Participants will continue their prescribed stable dose of methotrexate. The study is double-blind. Participants, investigators, and most study personnel will not know treatment assignment unless the information is needed to manage an urgent medical problem. A placebo contains no active RZ-417.\n\nVisits and procedures: Participants will attend 11 clinic visits. Procedures include medical-history review; physical examinations; vital signs; joint examinations; questionnaires about pain, fatigue, daily activities, and quality of life; blood and urine collection; pregnancy testing when applicable; electrocardiograms at screening and Week 20; and study-drug or placebo injections. Approximately 240 mL of blood will be collected over the entire study. Some blood samples will measure study-drug levels and immune responses; these tests are for research and would not ordinarily be part of routine arthritis care. Participants will record symptoms, medications, and injection reactions in an electronic diary. Each visit is expected to last 1 to 3 hours.\n\nKnown and possible risks: In earlier studies, commonly reported reactions associated with RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 changes immune-system activity, it may increase susceptibility to infection. Serious infection is possible. Allergic reactions, including rare severe reactions, may occur. Long-term risks and risks that are uncommon or not yet known cannot be ruled out because the medicine is investigational. Blood draws may cause temporary pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Answering questionnaires may cause boredom or emotional discomfort. Methotrexate has its own known risks, which the treating clinician will discuss separately.\n\nReproductive precautions: The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. Participants who could become pregnant must have a negative pregnancy test before treatment and use a highly effective contraceptive method during treatment and for 12 weeks after the final dose. Participants who could father a child must use effective contraception during the same period. Pregnancy must be reported to the study team immediately. Pregnant or breastfeeding individuals cannot participate.\n\nBenefits and alternatives: Participants may or may not experience improvement. Information learned may help future patients, but no benefit is promised. Alternatives include not joining, continuing current treatment, changing approved medicines with the participant’s clinician, or joining another study if eligible.\n\nVoluntary participation and withdrawal: Participation is voluntary. Refusal will not affect access to regular medical care or benefits. Participants may leave at any time without penalty. The investigator may end participation for safety concerns, failure to follow study requirements, pregnancy, study cancellation, or other reasons allowed by the protocol. Participants who stop treatment may be asked to complete safety assessments, but they may decline.\n\nCosts and payment: The sponsor will provide RZ-417 or placebo and research-only tests at no charge. Participants or their insurers remain responsible for usual medical care, including methotrexate and treatment unrelated to the research. Participants will receive $75 for each completed clinic visit, up to $825 total. Reasonable parking or public-transit expenses will be reimbursed with receipts, up to $30 per visit."
                }
            ]
        })


asyncio.run(main())

curl https://api.runware.ai/v1 \
  -H "Authorization: Bearer $RUNWARE_API_KEY" \
  -H "Content-Type: application/json" \
  -d '[
    {
      "taskType": "textInference",
      "taskUUID": "c320b53e-25a7-469d-8bb6-79e9c2cdffe2",
      "model": "xai:grok@4.3",
      "settings": {
        "thinkingLevel": "high",
        "maxTokens": 700
      },
      "messages": [
        {
          "role": "user",
          "content": "Rewrite the source material below as a participant-facing consent section for a Phase 2 rheumatoid arthritis study. This will be reviewed by an institutional review board and used during enrollment at U.S. research sites.\n\nWrite for an eighth-grade reading level while preserving every material fact, number, uncertainty, and distinction between research and standard care. Use respectful, neutral language. Do not imply that the study drug is effective, minimize risks, invent safeguards, or add medical facts not supplied here.\n\nOrganize the finished section under these exact headings:\n\nWhy is this study being done?\nWhat will happen if I join?\nWhat are the risks and discomforts?\nCould I benefit?\nWhat other choices do I have?\nCan I leave the study?\nWill I be paid or charged?\n\nDefine “placebo” at first use. Clearly explain the 2-to-1 random assignment in everyday language, state that neither the participant nor the study team will know the assignment during the study except when medically necessary, and distinguish research-only procedures from usual arthritis care. Use short paragraphs and bullets where they improve comprehension. Address the reader as “you.” Return only the finished consent section.\n\nSOURCE MATERIAL\n\nPurpose and design: The sponsor is evaluating RZ-417, an investigational injectable medicine, in adults with moderate-to-severe rheumatoid arthritis whose symptoms remain active despite stable methotrexate treatment. RZ-417 has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. Approximately 180 participants will be enrolled. Participation lasts up to 28 weeks: a screening period of up to 4 weeks, 20 weeks of study treatment, and a safety follow-up visit about 4 weeks after the final dose.\n\nAssignment and blinding: Eligible participants will be randomized in a 2:1 ratio to receive either RZ-417 or placebo by injection under the skin once every 2 weeks. Assignment is determined by chance. Participants will continue their prescribed stable dose of methotrexate. The study is double-blind. Participants, investigators, and most study personnel will not know treatment assignment unless the information is needed to manage an urgent medical problem. A placebo contains no active RZ-417.\n\nVisits and procedures: Participants will attend 11 clinic visits. Procedures include medical-history review; physical examinations; vital signs; joint examinations; questionnaires about pain, fatigue, daily activities, and quality of life; blood and urine collection; pregnancy testing when applicable; electrocardiograms at screening and Week 20; and study-drug or placebo injections. Approximately 240 mL of blood will be collected over the entire study. Some blood samples will measure study-drug levels and immune responses; these tests are for research and would not ordinarily be part of routine arthritis care. Participants will record symptoms, medications, and injection reactions in an electronic diary. Each visit is expected to last 1 to 3 hours.\n\nKnown and possible risks: In earlier studies, commonly reported reactions associated with RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 changes immune-system activity, it may increase susceptibility to infection. Serious infection is possible. Allergic reactions, including rare severe reactions, may occur. Long-term risks and risks that are uncommon or not yet known cannot be ruled out because the medicine is investigational. Blood draws may cause temporary pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Answering questionnaires may cause boredom or emotional discomfort. Methotrexate has its own known risks, which the treating clinician will discuss separately.\n\nReproductive precautions: The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. Participants who could become pregnant must have a negative pregnancy test before treatment and use a highly effective contraceptive method during treatment and for 12 weeks after the final dose. Participants who could father a child must use effective contraception during the same period. Pregnancy must be reported to the study team immediately. Pregnant or breastfeeding individuals cannot participate.\n\nBenefits and alternatives: Participants may or may not experience improvement. Information learned may help future patients, but no benefit is promised. Alternatives include not joining, continuing current treatment, changing approved medicines with the participant’s clinician, or joining another study if eligible.\n\nVoluntary participation and withdrawal: Participation is voluntary. Refusal will not affect access to regular medical care or benefits. Participants may leave at any time without penalty. The investigator may end participation for safety concerns, failure to follow study requirements, pregnancy, study cancellation, or other reasons allowed by the protocol. Participants who stop treatment may be asked to complete safety assessments, but they may decline.\n\nCosts and payment: The sponsor will provide RZ-417 or placebo and research-only tests at no charge. Participants or their insurers remain responsible for usual medical care, including methotrexate and treatment unrelated to the research. Participants will receive $75 for each completed clinic visit, up to $825 total. Reasonable parking or public-transit expenses will be reimbursed with receipts, up to $30 per visit."
        }
      ]
    }
  ]'

runware run xai:grok@4.3 \
  settings.thinkingLevel=high \
  settings.maxTokens=700 \
  messages.0.role=user \
  messages.0.content="Rewrite the source material below as a participant-facing consent section for a Phase 2 rheumatoid arthritis study. This will be reviewed by an institutional review board and used during enrollment at U.S. research sites.

Write for an eighth-grade reading level while preserving every material fact, number, uncertainty, and distinction between research and standard care. Use respectful, neutral language. Do not imply that the study drug is effective, minimize risks, invent safeguards, or add medical facts not supplied here.

Organize the finished section under these exact headings:

Why is this study being done?
What will happen if I join?
What are the risks and discomforts?
Could I benefit?
What other choices do I have?
Can I leave the study?
Will I be paid or charged?

Define “placebo” at first use. Clearly explain the 2-to-1 random assignment in everyday language, state that neither the participant nor the study team will know the assignment during the study except when medically necessary, and distinguish research-only procedures from usual arthritis care. Use short paragraphs and bullets where they improve comprehension. Address the reader as “you.” Return only the finished consent section.

SOURCE MATERIAL

Purpose and design: The sponsor is evaluating RZ-417, an investigational injectable medicine, in adults with moderate-to-severe rheumatoid arthritis whose symptoms remain active despite stable methotrexate treatment. RZ-417 has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. Approximately 180 participants will be enrolled. Participation lasts up to 28 weeks: a screening period of up to 4 weeks, 20 weeks of study treatment, and a safety follow-up visit about 4 weeks after the final dose.

Assignment and blinding: Eligible participants will be randomized in a 2:1 ratio to receive either RZ-417 or placebo by injection under the skin once every 2 weeks. Assignment is determined by chance. Participants will continue their prescribed stable dose of methotrexate. The study is double-blind. Participants, investigators, and most study personnel will not know treatment assignment unless the information is needed to manage an urgent medical problem. A placebo contains no active RZ-417.

Visits and procedures: Participants will attend 11 clinic visits. Procedures include medical-history review; physical examinations; vital signs; joint examinations; questionnaires about pain, fatigue, daily activities, and quality of life; blood and urine collection; pregnancy testing when applicable; electrocardiograms at screening and Week 20; and study-drug or placebo injections. Approximately 240 mL of blood will be collected over the entire study. Some blood samples will measure study-drug levels and immune responses; these tests are for research and would not ordinarily be part of routine arthritis care. Participants will record symptoms, medications, and injection reactions in an electronic diary. Each visit is expected to last 1 to 3 hours.

Known and possible risks: In earlier studies, commonly reported reactions associated with RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 changes immune-system activity, it may increase susceptibility to infection. Serious infection is possible. Allergic reactions, including rare severe reactions, may occur. Long-term risks and risks that are uncommon or not yet known cannot be ruled out because the medicine is investigational. Blood draws may cause temporary pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Answering questionnaires may cause boredom or emotional discomfort. Methotrexate has its own known risks, which the treating clinician will discuss separately.

Reproductive precautions: The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. Participants who could become pregnant must have a negative pregnancy test before treatment and use a highly effective contraceptive method during treatment and for 12 weeks after the final dose. Participants who could father a child must use effective contraception during the same period. Pregnancy must be reported to the study team immediately. Pregnant or breastfeeding individuals cannot participate.

Benefits and alternatives: Participants may or may not experience improvement. Information learned may help future patients, but no benefit is promised. Alternatives include not joining, continuing current treatment, changing approved medicines with the participant’s clinician, or joining another study if eligible.

Voluntary participation and withdrawal: Participation is voluntary. Refusal will not affect access to regular medical care or benefits. Participants may leave at any time without penalty. The investigator may end participation for safety concerns, failure to follow study requirements, pregnancy, study cancellation, or other reasons allowed by the protocol. Participants who stop treatment may be asked to complete safety assessments, but they may decline.

Costs and payment: The sponsor will provide RZ-417 or placebo and research-only tests at no charge. Participants or their insurers remain responsible for usual medical care, including methotrexate and treatment unrelated to the research. Participants will receive \$75 for each completed clinic visit, up to \$825 total. Reasonable parking or public-transit expenses will be reimbursed with receipts, up to \$30 per visit."

{
  "taskType": "textInference",
  "taskUUID": "c320b53e-25a7-469d-8bb6-79e9c2cdffe2",
  "model": "xai:grok@4.3",
  "settings": {
    "thinkingLevel": "high",
    "maxTokens": 700
  },
  "messages": [
    {
      "role": "user",
      "content": "Rewrite the source material below as a participant-facing consent section for a Phase 2 rheumatoid arthritis study. This will be reviewed by an institutional review board and used during enrollment at U.S. research sites.\n\nWrite for an eighth-grade reading level while preserving every material fact, number, uncertainty, and distinction between research and standard care. Use respectful, neutral language. Do not imply that the study drug is effective, minimize risks, invent safeguards, or add medical facts not supplied here.\n\nOrganize the finished section under these exact headings:\n\nWhy is this study being done?\nWhat will happen if I join?\nWhat are the risks and discomforts?\nCould I benefit?\nWhat other choices do I have?\nCan I leave the study?\nWill I be paid or charged?\n\nDefine “placebo” at first use. Clearly explain the 2-to-1 random assignment in everyday language, state that neither the participant nor the study team will know the assignment during the study except when medically necessary, and distinguish research-only procedures from usual arthritis care. Use short paragraphs and bullets where they improve comprehension. Address the reader as “you.” Return only the finished consent section.\n\nSOURCE MATERIAL\n\nPurpose and design: The sponsor is evaluating RZ-417, an investigational injectable medicine, in adults with moderate-to-severe rheumatoid arthritis whose symptoms remain active despite stable methotrexate treatment. RZ-417 has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. Approximately 180 participants will be enrolled. Participation lasts up to 28 weeks: a screening period of up to 4 weeks, 20 weeks of study treatment, and a safety follow-up visit about 4 weeks after the final dose.\n\nAssignment and blinding: Eligible participants will be randomized in a 2:1 ratio to receive either RZ-417 or placebo by injection under the skin once every 2 weeks. Assignment is determined by chance. Participants will continue their prescribed stable dose of methotrexate. The study is double-blind. Participants, investigators, and most study personnel will not know treatment assignment unless the information is needed to manage an urgent medical problem. A placebo contains no active RZ-417.\n\nVisits and procedures: Participants will attend 11 clinic visits. Procedures include medical-history review; physical examinations; vital signs; joint examinations; questionnaires about pain, fatigue, daily activities, and quality of life; blood and urine collection; pregnancy testing when applicable; electrocardiograms at screening and Week 20; and study-drug or placebo injections. Approximately 240 mL of blood will be collected over the entire study. Some blood samples will measure study-drug levels and immune responses; these tests are for research and would not ordinarily be part of routine arthritis care. Participants will record symptoms, medications, and injection reactions in an electronic diary. Each visit is expected to last 1 to 3 hours.\n\nKnown and possible risks: In earlier studies, commonly reported reactions associated with RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 changes immune-system activity, it may increase susceptibility to infection. Serious infection is possible. Allergic reactions, including rare severe reactions, may occur. Long-term risks and risks that are uncommon or not yet known cannot be ruled out because the medicine is investigational. Blood draws may cause temporary pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Answering questionnaires may cause boredom or emotional discomfort. Methotrexate has its own known risks, which the treating clinician will discuss separately.\n\nReproductive precautions: The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. Participants who could become pregnant must have a negative pregnancy test before treatment and use a highly effective contraceptive method during treatment and for 12 weeks after the final dose. Participants who could father a child must use effective contraception during the same period. Pregnancy must be reported to the study team immediately. Pregnant or breastfeeding individuals cannot participate.\n\nBenefits and alternatives: Participants may or may not experience improvement. Information learned may help future patients, but no benefit is promised. Alternatives include not joining, continuing current treatment, changing approved medicines with the participant’s clinician, or joining another study if eligible.\n\nVoluntary participation and withdrawal: Participation is voluntary. Refusal will not affect access to regular medical care or benefits. Participants may leave at any time without penalty. The investigator may end participation for safety concerns, failure to follow study requirements, pregnancy, study cancellation, or other reasons allowed by the protocol. Participants who stop treatment may be asked to complete safety assessments, but they may decline.\n\nCosts and payment: The sponsor will provide RZ-417 or placebo and research-only tests at no charge. Participants or their insurers remain responsible for usual medical care, including methotrexate and treatment unrelated to the research. Participants will receive $75 for each completed clinic visit, up to $825 total. Reasonable parking or public-transit expenses will be reimbursed with receipts, up to $30 per visit."
    }
  ]
}

Response

{
  "taskType": "textInference",
  "taskUUID": "c320b53e-25a7-469d-8bb6-79e9c2cdffe2",
  "text": "Why is this study being done?\n\nThe sponsor is testing an investigational medicine called RZ-417 in adults with moderate-to-severe rheumatoid arthritis whose symptoms continue despite stable methotrexate treatment. RZ-417 is not approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. About 180 people will take part. The study lasts up to 28 weeks: up to 4 weeks to check if you can join, 20 weeks of study treatment, and one safety visit about 4 weeks after the last dose.\n\nWhat will happen if I join?\n\nIf you join, you will continue your current stable dose of methotrexate. You will be assigned by chance to get either RZ-417 or placebo. A placebo looks like the study medicine but contains no active RZ-417. Two out of every three people will get RZ-417 and one out of every three will get placebo. Neither you nor the study team will know which one you receive while the study is running, unless the information is needed right away for an urgent medical problem.\n\nYou will come to the clinic 11 times. At these visits the team will review your medical history, do physical and joint exams, check vital signs, ask questions about pain, fatigue, daily activities, and quality of life, collect blood and urine, do pregnancy testing if needed, and record an electrocardiogram at the first and last treatment visits. About 240 mL of blood will be taken over the whole study. Some of the blood tests measure study-drug levels and immune responses; these tests are for research only and would not be done in usual arthritis care. You will also record symptoms, medicines, and any injection reactions in an electronic diary. Each visit should take 1 to 3 hours. You will get study injections under the skin every 2 weeks.\n\nWhat are the risks and discomforts?\n\nIn earlier studies the most common reactions linked to RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 affects the immune system, it may raise the chance of infection, including serious infection. Allergic reactions, including rare severe ones, can occur. Long-term risks and risks that are uncommon or still unknown cannot be ruled out because the medicine is investigational.\n\nBlood draws can cause brief pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Filling out questionnaires may cause boredom or emotional discomfort. Methotrexate has its own risks; your regular doctor will discuss those with you.\n\nThe effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. People who could become pregnant must have a negative pregnancy test before starting and use a highly effective birth-control method during treatment and for 12 weeks after the last dose. People who could father a child must use effective birth control during the same time. Pregnancy must be reported to the study team right away. Pregnant or breastfeeding individuals cannot join.\n\nCould I benefit?\n\nYou may or may not feel any improvement in your arthritis. The information learned may help future patients, but no benefit is promised.\n\nWhat other choices do I have?\n\nYou do not have to join. You can continue your current treatment, change to other approved medicines with your clinician, or look for another study if you are eligible.\n\nCan I leave the study?\n\nJoining is voluntary. Saying no will not affect your regular medical care",
  "cost": 0.00312685,
  "finishReason": "length",
  "reasoningContent": [
    "The task is to rewrite the source material into a participant-facing consent section for a Phase 2 rheumatoid arthritis study. It must be at an eighth-grade reading level, preserve all material facts,...Why is this study being done?\n\nThis study is testing an investigational medicine called RZ-417. It is an injectable drug given under the skin. It has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition."
  ]
}

tool-calling

Newsroom Embargo Timestamp Lookup$0.000206~4s

Reasoning

The task is: "Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second,...

{
  "taskType": "textInference",
  "taskUUID": "1312b239-3d56-4998-ad89-f9d64ed5165c",
  "cost": 0.0002059,
  "finishReason": "tools",
  "reasoningContent": [
    "The task is: \"Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second,..."
  ],
  "tools": [
    {
      "id": "call-7f1252fe-af96-48a9-a304-de6bf8c69efc-0",
      "name": "get_current_utc_time"
    }
  ]
}

Finish reason: tools

Try in Playground

import { createClient } from '@runware/sdk'

const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()

const [result] = await client.run({
  model: 'xai:grok@4.3',
  settings: {
    temperature: 0.2,
    thinkingLevel: 'low',
    maxTokens: 300
  },
  messages: [
    {
      role: 'user',
      content: 'Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second, so our publishing system can record the official release timestamp.'
    }
  ],
  tools: [
    {
      type: 'function',
      name: 'get_current_utc_time',
      description: 'Returns the current date and time in UTC.',
      schema: {}
    }
  ],
  toolChoice: {
    type: 'tool',
    name: 'get_current_utc_time'
  }
})

import asyncio
import os

from runware import Runware


async def main():
    async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
        results = await client.run({
            "model": "xai:grok@4.3",
            "settings": {
                "temperature": 0.2,
                "thinkingLevel": "low",
                "maxTokens": 300
            },
            "messages": [
                {
                    "role": "user",
                    "content": "Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second, so our publishing system can record the official release timestamp."
                }
            ],
            "tools": [
                {
                    "type": "function",
                    "name": "get_current_utc_time",
                    "description": "Returns the current date and time in UTC.",
                    "schema": {}
                }
            ],
            "toolChoice": {
                "type": "tool",
                "name": "get_current_utc_time"
            }
        })


asyncio.run(main())

curl https://api.runware.ai/v1 \
  -H "Authorization: Bearer $RUNWARE_API_KEY" \
  -H "Content-Type: application/json" \
  -d '[
    {
      "taskType": "textInference",
      "taskUUID": "1312b239-3d56-4998-ad89-f9d64ed5165c",
      "model": "xai:grok@4.3",
      "settings": {
        "temperature": 0.2,
        "thinkingLevel": "low",
        "maxTokens": 300
      },
      "messages": [
        {
          "role": "user",
          "content": "Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second, so our publishing system can record the official release timestamp."
        }
      ],
      "tools": [
        {
          "type": "function",
          "name": "get_current_utc_time",
          "description": "Returns the current date and time in UTC.",
          "schema": {}
        }
      ],
      "toolChoice": {
        "type": "tool",
        "name": "get_current_utc_time"
      }
    }
  ]'

runware run xai:grok@4.3 \
  settings.temperature=0.2 \
  settings.thinkingLevel=low \
  settings.maxTokens=300 \
  messages.0.role=user \
  messages.0.content="Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second, so our publishing system can record the official release timestamp." \
  tools.0.type=function \
  tools.0.name=get_current_utc_time \
  tools.0.description="Returns the current date and time in UTC." \
  toolChoice.type=tool \
  toolChoice.name=get_current_utc_time

{
  "taskType": "textInference",
  "taskUUID": "1312b239-3d56-4998-ad89-f9d64ed5165c",
  "model": "xai:grok@4.3",
  "settings": {
    "temperature": 0.2,
    "thinkingLevel": "low",
    "maxTokens": 300
  },
  "messages": [
    {
      "role": "user",
      "content": "Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second, so our publishing system can record the official release timestamp."
    }
  ],
  "tools": [
    {
      "type": "function",
      "name": "get_current_utc_time",
      "description": "Returns the current date and time in UTC.",
      "schema": {}
    }
  ],
  "toolChoice": {
    "type": "tool",
    "name": "get_current_utc_time"
  }
}

Response

{
  "taskType": "textInference",
  "taskUUID": "1312b239-3d56-4998-ad89-f9d64ed5165c",
  "cost": 0.0002059,
  "finishReason": "tools",
  "reasoningContent": [
    "The task is: \"Our international desk is lifting the embargo on the Helios Energy acquisition announcement immediately. Retrieve the current UTC date and time in RFC 3339 format, precise to the second,..."
  ],
  "tools": [
    {
      "id": "call-7f1252fe-af96-48a9-a304-de6bf8c69efc-0",
      "name": "get_current_utc_time"
    }
  ]
}

tool-calling

Pharmaceutical Recall Timestamp Record$0.000236~4s

Reasoning

The task is: "Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authorita...

{
  "taskType": "textInference",
  "taskUUID": "78aa0396-d278-44f0-b92d-f9aa681292d8",
  "cost": 0.0002359,
  "finishReason": "tools",
  "reasoningContent": [
    "The task is: \"Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authorita..."
  ],
  "tools": [
    {
      "id": "call-dfb29085-8ca9-4646-b6ff-ee982af774a6-0",
      "name": "get_current_utc_time"
    }
  ]
}

Finish reason: tools

Try in Playground

import { createClient } from '@runware/sdk'

const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()

const [result] = await client.run({
  model: 'xai:grok@4.3',
  settings: {
    temperature: 0.2,
    thinkingLevel: 'low',
    maxTokens: 300
  },
  messages: [
    {
      role: 'user',
      content: 'Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authoritative time service and record it as the recall activation timestamp. Do not estimate the time or derive it from the conversation.'
    }
  ],
  tools: [
    {
      type: 'function',
      name: 'get_current_utc_time',
      description: 'Returns the current date and time in UTC.',
      schema: {}
    }
  ],
  toolChoice: {
    type: 'tool',
    name: 'get_current_utc_time'
  }
})

import asyncio
import os

from runware import Runware


async def main():
    async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
        results = await client.run({
            "model": "xai:grok@4.3",
            "settings": {
                "temperature": 0.2,
                "thinkingLevel": "low",
                "maxTokens": 300
            },
            "messages": [
                {
                    "role": "user",
                    "content": "Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authoritative time service and record it as the recall activation timestamp. Do not estimate the time or derive it from the conversation."
                }
            ],
            "tools": [
                {
                    "type": "function",
                    "name": "get_current_utc_time",
                    "description": "Returns the current date and time in UTC.",
                    "schema": {}
                }
            ],
            "toolChoice": {
                "type": "tool",
                "name": "get_current_utc_time"
            }
        })


asyncio.run(main())

curl https://api.runware.ai/v1 \
  -H "Authorization: Bearer $RUNWARE_API_KEY" \
  -H "Content-Type: application/json" \
  -d '[
    {
      "taskType": "textInference",
      "taskUUID": "78aa0396-d278-44f0-b92d-f9aa681292d8",
      "model": "xai:grok@4.3",
      "settings": {
        "temperature": 0.2,
        "thinkingLevel": "low",
        "maxTokens": 300
      },
      "messages": [
        {
          "role": "user",
          "content": "Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authoritative time service and record it as the recall activation timestamp. Do not estimate the time or derive it from the conversation."
        }
      ],
      "tools": [
        {
          "type": "function",
          "name": "get_current_utc_time",
          "description": "Returns the current date and time in UTC.",
          "schema": {}
        }
      ],
      "toolChoice": {
        "type": "tool",
        "name": "get_current_utc_time"
      }
    }
  ]'

runware run xai:grok@4.3 \
  settings.temperature=0.2 \
  settings.thinkingLevel=low \
  settings.maxTokens=300 \
  messages.0.role=user \
  messages.0.content="Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authoritative time service and record it as the recall activation timestamp. Do not estimate the time or derive it from the conversation." \
  tools.0.type=function \
  tools.0.name=get_current_utc_time \
  tools.0.description="Returns the current date and time in UTC." \
  toolChoice.type=tool \
  toolChoice.name=get_current_utc_time

{
  "taskType": "textInference",
  "taskUUID": "78aa0396-d278-44f0-b92d-f9aa681292d8",
  "model": "xai:grok@4.3",
  "settings": {
    "temperature": 0.2,
    "thinkingLevel": "low",
    "maxTokens": 300
  },
  "messages": [
    {
      "role": "user",
      "content": "Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authoritative time service and record it as the recall activation timestamp. Do not estimate the time or derive it from the conversation."
    }
  ],
  "tools": [
    {
      "type": "function",
      "name": "get_current_utc_time",
      "description": "Returns the current date and time in UTC.",
      "schema": {}
    }
  ],
  "toolChoice": {
    "type": "tool",
    "name": "get_current_utc_time"
  }
}

Response

{
  "taskType": "textInference",
  "taskUUID": "78aa0396-d278-44f0-b92d-f9aa681292d8",
  "cost": 0.0002359,
  "finishReason": "tools",
  "reasoningContent": [
    "The task is: \"Open the official action log for recall RC-2026-017 covering Cardiomab 50 mg prefilled syringes, lots CM50-24081 and CM50-24082. Retrieve the current UTC date and time from the authorita..."
  ],
  "tools": [
    {
      "id": "call-dfb29085-8ca9-4646-b6ff-ee982af774a6-0",
      "name": "get_current_utc_time"
    }
  ]
}